RNF213 ‐Dependent EGFR and HER2 Activation Regulates Specific Downstream Signaling Pathways in Human Cancer Cells
Genes to Cells · 2025
DOI: 10.1111/gtc.70033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes to Cells, 2025. Verfasst von Intisar M Fouad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Biosciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: ErbB Receptors, Ubiquitin-Protein Ligases, Signal Transduction, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
In this study, we reveal a novel relationship between RNF213, an E3 ubiquitin ligase associated with Moyamoya disease (MMD) and the ubiquitination of both endogenous and pathogenic substrates, and EGFR, the epithelial growth factor receptor involved in cell growth, angiogenesis, and cancer. RNF213 knockdown or knockout in HeLa and A549 cells markedly reduces EGFR phosphorylation at key tyrosine sites following EGF and TGFα stimulation. In RNF213 knockout cells, HER2 phosphorylation, typically activated through heterodimerization with EGFR, and Src recruitment and/or phosphorylation are also diminished. Mutations in the RNF213 RING, RZ finger, or AAA+ domains, including the prevalent R4810K mutation in MMD, consistently reduce EGFR phosphorylation. In vivo, EGF injections increase EGFR and HER2 phosphorylation in WT but not in RNF213 knockout mice. Despite the reduced phosphorylation levels of these tyrosine kinases in knockout cells, the activation of downstream signals such as AKT, ERK1/2, and STAT3 remains unaffected, although phosphorylation of PLCγ, a key mediator of Ca 2+ release, is selectively reduced by RNF213 knockout. These findings demonstrate that RNF213 modulates EGFR‐related pathways and specific downstream signal pathways, possibly affecting physiologic and pathogenic angiogenesis, and may have implications for unraveling the etiology of MMD and for developing cancer therapies that target RNF213.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Biosciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Laboratory of Molecular Biology of Bioresponse, Graduate School of Biostudies, Kyoto University, Kyoto, Japan.
- Laboratory of Integrative Molecular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Food and Nutrition, Faculty of Agriculture, Kindai University, Osaka, Japan.
- Laboratory of Science Communication, Department of Biology Education and Heredity, Graduate School of Biostudies, Kyoto University, Kyoto, Japan.
- Department of Artificial Intelligence in Healthcare and Medicine and Kyoto University, Kyoto, Japan.
ORCID-Profile: Minsoo Kim, Tohru Tezuka, Shohab Youssefian
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Fouad, I. M., Choi, J., Huang, Q., Kim, M., Masuda, S., Hejna, J. A., Mineharu, Y., Koizumi, A., Tezuka, T., & Youssefian, S. (2025). RNF213 ‐Dependent EGFR and HER2 Activation Regulates Specific Downstream Signaling Pathways in Human Cancer Cells. Genes to Cells. https://doi.org/10.1111/gtc.70033
Vancouver
Fouad IM, Choi J, Huang Q, Kim M, Masuda S, Hejna JA, et al. RNF213 ‐Dependent EGFR and HER2 Activation Regulates Specific Downstream Signaling Pathways in Human Cancer Cells. Genes to Cells. 2025. doi:10.1111/gtc.70033
BibTeX
@article{Fouad2025,
author = {Fouad, Intisar M and Choi, Jungmi and Huang, Qianying and Kim, Minsoo and Masuda, Seiji and Hejna, James A and Mineharu, Yohei and Koizumi, Akio and Tezuka, Tohru and Youssefian, Shohab},
title = {RNF213 ‐Dependent EGFR and HER2 Activation Regulates Specific Downstream Signaling Pathways in Human Cancer Cells},
journal = {Genes to Cells},
year = {2025},
doi = {10.1111/gtc.70033}
}
EUVIMED